Different switching rate of anti-TNF-α drugs in monotherapy and in combination with methotrexate in a cohort of rheumatoid arthritis patients in the real life

Joint Bone Spine

Volumn 81, Issue 5, 2014, Pages 458-459

  Iannone, Florenzo ^a   Notarnicola, Antonella ^a   Lopalco, Giuseppe ^a   Lapadula, Giovanni ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Anti TNF; Monotherapy; Rheumatoid arthritis

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; METHOTREXATE; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

AGE; BODY MASS; DISEASE ACTIVITY; DISEASE DURATION; DRUG SUBSTITUTION; HUMAN; LETTER; MONOTHERAPY; PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; SEX DIFFERENCE; SURVIVAL; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME; ADULT; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; DRUG ADMINISTRATION; DRUG COMBINATION; FEMALE; MALE; MIDDLE AGED; RETROSPECTIVE STUDY;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; RETROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84927698391     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2014.01.012     Document Type: Letter

References (9)

1. Emery P., Sebba A., Huizinga T.W. Biologic and oral disease-modifying anti-rheumatic drug monotherapy in rheumatoid arthritis. Ann Rheum Dis 2013, 72:1897-1904.
2. Kaufmann J., Feist E., Roske A.E., et al. Monotherapy with tocilizumab or TNF-alpha inhibitors in patients with rheumatoid arthritis: efficacy, treatment satisfaction, and persistence in routine clinical practice. Clin Rheumatol 2013, 32:1347-1355.
3. Koike T., Harigai M., Inokuma S., et al. Safety and effectiveness of 6 months' etanercept monotherapy and combination therapy in Japanese patients with rheumatoid arthritis: effect of concomitant disease-modifying anti-rheumatic drugs. J Rheumatol 2013, 40:1658-1668.
4. Gómez-Reino J. Biologic monotherapy as initial treatment in patients with early rheumatoid arthritis. Rheumatology (Oxford) 2012, 51:v31-v37.
5. van der Heijde D., Burmester G., Melo-Gomes J., et al. The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy. Ann Rheum Dis 2008, 67:182-188.
6. Emery P., Breedveld F.C., Hall S., et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008, 372:375-382.
7. Hyrich K.L., Symmons D.P., Watson K.D., et al. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006, 54:1786-1794.
8. van de Putte L.B., Atkins C., Malaise M., et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying anti-rheumatic drug treatment has failed. Ann Rheum Dis 2004, 63:508-516.
9. Arnett F.C., Edworthy S.M., Bloch D.A., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.